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Abstract
Background: Vomiting in children with acute gastroenteritis (AG) is not only a direct cause of fluid loss but it is
also a major factor of failure of oral rehydration therapy (ORT). Physicians who provide care to paediatric patients in
the emergency department (ED) usually prescribe intravenous fluid therapy (IVT) for mild or moderate dehydration
when vomiting is the major symptom. Thus, effective symptomatic treatment of vomiting would lead to an
important reduction in the use of IVT and, consequently, of the duration of hospital stay and of frequency of
hospital admission. Available evidence on symptomatic treatment of vomiting shows the efficacy of the most
recently registered molecule (ondansetron) but a proper evaluation of antiemetics drugs largely used in clinical
practice, such as domperidone, is lacking.
Objectives: To compare the efficacy of ondansetron and domperidone for the symptomatic treatment of vomiting
in children with AG who have failed ORT.
Methods/Design: Multicentre, double-blind randomized controlled trial conducted in paediatric EDs. Children
aged from 1 to 6 years who vomiting, with a presumptive clinical diagnosis of AG, and without severe dehydration
will be included. After the failure of a initial ORS administration in ED, eligible children will be randomized to
receive: 1) ondansetron syrup (0,15 mg/Kg of body weight); 2) domperidone syrup (0,5 mg/Kg of body weight);
3) placebo. The main study outcome will be the percentage of patients needing nasogastric or IVT after symptomatic
oral treatment failure, defined as vomiting or fluid refusal after a second attempt of ORT. Data relative to study
outcomes will be collected at 30 minute intervals for a minimum of 6 hours. A telephone follow up call will be made
48 hours after discharge. A total number of 540 children (i.e. 180 patients in each arm) will be enrolled.
Discussion: The trial results would provide evidence on the efficacy of domperidone, which is largely used in
clinical practice despite the lack of proper evaluation and a controversial safety profile, as compared to
ondansetron, which is not yet authorized in Italy despite evidence supporting its efficacy in treating vomiting. The
trial results would contribute to a reduction in the use of IVT and, consequently, in hospital admissions in children
with AG. The design of this RCT, which closely reflect current clinical practice in EDs, will allow immediate
transferability of results.
Trial Registration: ClinicalTrials.gov: NCT01257672
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Acute Gastroenteritis
Acute gastroenteritis (AG) is the main cause of acute
vomiting in children aged under 3 years and one of the
most important reasons for access to the emergency
department (ED) and admission to hospital.
In USA 1.5 millions of children under 5 years are
diagnosed AG annually and 13% of these children are
admitted to the hospital [1]. In Italy “esophagitis, gastro-
enteritis and a miscellaneous of digestive apparatus dis-
eases” results to be the most important cause of hospital
admission in paediatric age [2].
The World Health Organization (WHO), the Ameri-
can Academy of Pediatrics (AAP), and the European
Society for Paediatric Gastroenterology, Hepatology, and
Nutrition (ESPGHAN) working group and the Cochrane
Library database recommend oral rehydration therapy
(ORT) and prompt realimentation for mild to moderate
gastroenteritis [3,4].
Vomiting in gastroenteritis and need for pharmacological
treatment
In the initial phase of viral AG, vomiting is a typical
symptom [5]. Thus, in AG caused by rotavirus infection
during the first 1 to 3 days, repeated vomiting is present
in 75% of children [6]. Current practice recommenda-
tions for paediatric AG do not include pharmacologic
treatment for vomiting [3]. However, vomiting from AG
is distressing for patients and their families. In addition,
vomiting is not only a direct cause of fluid loss but can
also hamper successful oral rehydration therapy and it is
a major factor of failure of ORT. Many physicians
believe that vomiting is a contraindication to ORT. Phy-
sicians who provide care to paediatric patients in the
emergency department consistently favour intravenous
fluid therapy (IVT) for mild or moderate dehydration
when vomiting is the major symptom [7,8]. Thus, effec-
tive treatment of vomiting would lead to an important
reduction in the use of IVT. Antiemetic agents and their
use in clinical practice. Various antiemetic agents have
been used to prevent or reduce vomiting in children
with gastroenteritis [9]. The phenothiazines are dopa-
mine antagonists and act centrally by blocking the che-
moreceptor trigger zone. They are used to prevent or
treat vomiting associated with drugs such as opiates,
general anaesthetics, and cytotoxics. Unfortunately,
severe dystonic reactions sometimes occur with phe-
nothiazines, especially in children.
Metoclopramide is a chlorinated procainamide derivative
that acts primarily as a dopamine D2 receptor antagonist
and has both central and peripheral actions. Metoclopra-
mide also acts directly on the gastro-intestinal tract and
it may be more effective than the phenothiazines for
vomiting associated with gastro-duodenal disease. As with
the phenothiazines, metoclopramide can induce acute dys-
tonic reactions involving facial and skeletal muscle spasms
a n do c u l o g y r i cc r i s e s .T h e s ed y s t o n i ce f f e c t sa r em o r e
common in paediatric age. In Italy metoclopramide use in
children under 16 years old is not recommended because
severe extrapyramidal reactions [10] were reported in case-
control studies and case reports. Domperidone is a D2
receptor antagonist that acts on the chemoreceptor trigger
zone. The medication also accelerates gastric emptying.
Ondansetron is a specific 5HT3 antagonists which block
5HT3 receptors in the gastro-intestinal tract and in the
central nervous system. It has been shown to be effective
in the treatment of vomiting in patients receiving cytotoxic
agents for cancer. Dexamethasone also has anti-emetic
effects and is used to prevent vomiting associated with can-
cer chemotherapy. In this context it may be used alone or
with other anti-emetics such as metoclopramide or a
5HT3 antagonist.
In the clinical practice antiemetic drugs are frequently
used in children with gastroenteritis. A recent retrospec-
tive survey retrieved data from 4 national and interna-
tional databases showed that prescription of antiemetic
medication varied considerably [11]. In particular,
b e t w e e n2 %a n d2 3 %o fc h i l d ren with gastroenteritis
received prescriptions for antiemetic medications. The
antihistamines dimenhydrinate and diphenhydramine
were most frequently used in Germany and Canada,
whereas promethazine was prescribed preferentially in
the United States. In France, Spain, and Italy, the dopa-
mine receptor antagonist domperidone was preferred as
antiemetic treatment. Ondansetron was used in a minor
proportion of antiemetic prescriptions. A recent survey
carried out in Italy showed that 79% of participating
clinicians prescribe antiemetic drugs to treat acute gas-
troenteritis (domperidone in primis followed by meto-
clopramide) [12]. Data on Italian prescriptions collected
by ARNO confirmed that among gastrointestinal agents,
prokinetics (in 80% of cases domperidone) are the most
prescribed in clinical practice [13].
Antiemetic drugs in acute gastroenteritis: evidence of efficacy
As demonstrated in 3 recently published meta-analysis, lit-
erature evaluating the efficacy of symptomatic drugs in
reducing acute vomiting for AG in paediatric age is meth-
odologically limited and focuses mainly on ondansetron
[14-16]. The 11 articles meeting the inclusion criteria eval-
uated various antiemetic agents [16]: ondansetron (n = 6),
domperidone (n = 2), metoclopramide (n = 2), trimetho-
benzamide (n = 2), pyrilamine-pentobarbital (n = 2), dexa-
methasone (n = 1), and promethazine (n = 1). Six
randomised controlled trials (RCTs) were carried out
to evaluate ondansetron use in a total population of
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tron versus placebo. Furthermore two RCTs included the
comparison of ondansetron to metoclopramide and dexa-
methasone [16]. In three studies ondansetron was admini-
strated per os and in the other three intravenous
administration was preferred. Ondansetron, compared to
placebo reduces the risk of future vomiting episodes (RR:
0.45; 95% CI: 0.33-0.62; Number Need to Treat, NNT =
5), the number of patients needing intravenous rehydra-
tion (RR, 0.41; 95% CI: 0.28 0.62; NNT = 5) and hospital
admissions (RR, 0.52; 95% CI: 0.27-0.95; NNT = 14) [16].
The drug is not effective in reducing the access to ED for
acute vomiting [14-16]. With respect to side effects, except
for the greater incidence of diarrhoea in patients receiving
ondansetron treatment [16], no other significant differ-
ences no other significant differences between ondanse-
tron and placebo were identified.
A few studies were published regarding domperidone
[23,24] and metoclopramide [21,23] and were character-
ized by small sample sizes, low methodological quality,
and produced inconsistent results. These methodological
issues do not allow to draw any conclusions about the
risks/benefits balance of the two drugs [16]. Further-
more, an adequate comparative evaluation between
domperidone, metoclopramide and ondansetron is miss-
ing. All the studies included in the analysis were funded
by pharmaceutical companies.
The need for further evidence and potential
transferability to clinical practice
T h ea b o v er e p o r t e de v i d e n c es h o w st h ee f f i c a c yo ft h e
most recently registered molecule (ondansetron), but
the studies were carried out on very heterogeneous
populations for which risks, costs and benefits were not
sufficiently assessed. The same evidence showed that a
proper evaluation of anti-emetics drugs largely used in
clinical practice [13], such as domperidone, is comple-
tely lacking. This lack of knowledge about antiemetics is
particularly important considering the restricted indica-
tions for their use in Italy (this is particularly true for
metoclopramide). In fact, these agents’ potential side
effects as extra-pyramidal manifestations, lack of con-
sciousness, convulsions are mostly dose-dependent and
they have been addressed by ad hoc report by Italian
Agency of Drug (AIFA) paediatric commission [25].
In light of the above considerations, we propose a
multicentre study comparing the efficacy of ondansetron
and domperidone for the symptomatic treatment of
vomiting in acute gastroenteritis. The study aims at
answering the following clinical questions: a) would
anti-emetics agents reduce the percentage of children
who keep vomiting? b) would anti-emetics treatment
favour the oral rehydration and reduce the need for
nasogastric or intravenous fluid rehydration? c) would
the treatment reduce the percentage of children acces-
sing health services and needing hospital admission?
We believe that the results of such a trial could signif-
icantly impact current clinical practice. In fact it would
define the real efficacy of domperidone largely used in
clinical practice (despite the lack of a clear evidence-
based assessment and a controversial safeness profile)
compared to ondansetron whose use to treat vomiting
in AG is not yet authorized in Italy despite evidence
supporting its possible use.
Objectives of the study
Primary Objective
To evaluate whether the oral administration of a symp-
tomatic drug (ondansetron or domperidone) prevents
intravenous or nasogastric rehydration in children
vomiting and diagnosed acute gastroenteritis.
Secondary Objective
To assess whether the oral administration of a sympto-
matic drug (ondansetron or domperidone) reduces the
total duration and number of vomiting episodes and the
need for hospital admission or ED access.
Methods/Design
Study Design
The study is a prospective, multicentre, double-blind
randomized controlled trial. The study will be coordi-
nated by the Institute for Maternal and Child Health -
IRCCS Burlo Garofolo (Trieste) and by the Maternal
and Child Health Laboratory of the Institute Mario
Negri (Milan).
Ethical approval
Multi-centre approval has been granted by the Bioethics
Committee of the Coordinating centre (Institute for
Maternal and Child Health IRCCS Burlo Garofolo,
Trieste), on November 8, 2010 (registration number:
S-115). Site-specific approval has been granted by local
Ethic Committee at all trial sites.
Study Population
The study will be conducted in hospital and the recruit-
ment setting will be the paediatric emergency depart-
ments (ED). Children between 1 to 6 years will be
included in the study. Consecutive subjects accessing
the ED during a 18 months period will be evaluated for
inclusion/exclusion criteria by the doctor on call. The
following inclusion and exclusion criteria will be used
Inclusion Criteria
1) Age from 1 to 6 years;
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teritis in patients with vomiting, with or without
diarrhoea (Table 1);
3) more than three episodes of non-bilious, non-
bloody vomiting within the previous 24 hours;
Exclusion Criteria
1) Treatment with antiemetics or antidiarrhoic drugs
in the 6 hours prior to access to ED;
2) underlying chronic diseases (eg, malignancy, gas-
troesophageal reflux, migraine, renal failure, hypoal-
buminemia, liver disease);
3) severe dehydration: weight loss >10% or standar-
dized clinical dehydration score > = 18 for children
aged 12-24 months and > = 16 for older children [20];
4) known hypersensitivity to ondansetron or
domperidone;
5) previous enrolment in the study
Intervention
After checking the inclusion and exclusion criteria,
administration of oral rehydration solution (ORS) will
be started following a standard protocol (Table 1). ORS
will be prescribed by the doctor on call and adminis-
tered under supervision of an emergency departments
nurse. In case of failure of the initial ORS administra-
tion, defined as: 1) vomiting after ORS, assessed by the
doctor on call or the emergency departments nurse
based on the definition reported in Table 1; or 2) fluid
refusal after three attempts), patients will be randomized
to receive an oral administration of:
1) ondansetron syrup (0,15 mg/Kg of body weight);
2) domperidone syrup (0,5 mg/Kg of body weight);
3) placebo.
Children vomiting within 15 minutes after receiving the
drug will be given a second dose. After 45 to 60 minutes
from treatment administration, a new attempt to admin-
ister ORS will be done, according to the standard proto-
col (Table 1). After an adequate information of the study
and before random allocation of subjects, written consent
will be obtained by the doctor on call from the parents or
legal guardian of children fulfilling the entry criteria and
failing initial ORS administration. A register of all
patients who were proposed to be enrolled in the study
will be kept, and reason for refusal will be recorded.
A flow chart describing comparison groups and trial
procedures is reported in Figure 1.
Outcomes
Primary Outcome
Percentage of patients needing nasogastric or intrave-
nous rehydration after symptomatic oral treatment fail-
ure, defined as vomiting or fluid refusal after the second
attempt of ORT.
Secondary Outcomes
1) Percentage of subjects needing hospital admission
for the same illness;
2) Percentage of subjects needing observation stay
for more than 6 hours for the same illness;
3) Total emesis duration in the 3 allocation groups;
4) Number of episodes of vomiting in the 3 treat-
ment groups during the follow-up period;
5) Percentage of subjects presenting adverse events.
Table 1 Definitions of clinical diagnosis of acute
gastroenteritis, vomiting, and standard protocol of oral
rehydration solution administration
Clinical diagnosis of acute gastroenteritis
We refer to the NICE guideline (http://www.nice.org.uk/guidance/index.
jsp?action=download&o=42316) that recommends:
When considering a diagnosis of gastroenteritis, look for the following key
characteristics:
A recent change in stool consistency to loose or watery stools; recent
onset of vomiting; recent contact with an individual with acute
diarrhoea; exposure to known source of enteric infection (water or food
borne); recent foreign travel.
Consider the following symptoms and signs as possible indicators of
diagnoses other than gastroenteritis:
High fever (age less than 3 months: >38°C; age more than 3 months:
>39°C); rapid breathing or labored respirations; altered conscious level
(irritability, drowsiness); photophobia, neck stiffness and/or bulging
fontanelle (in infants); non-blanching (haemorrhagic) rash; blood and/or
mucous in stool; bilious vomiting (green); severe or localized abdominal
pain; abdominal distension or rebound tenderness.”
Definition of Vomiting
According to NICE, we define vomiting as the forceful ejection of the
stomach contents up to and out of the mouth (http://www.nice.org.uk/
guidance/index.jsp?action=download&o=42316).
Episodes separated by no more than two minutes are counted as a
single episode. Non-productive retching, spilling of oral contents, and
drooling were not considered vomiting.
Standard protocol of oral rehydration solution (ORS)
administration
The following standard protocol is the result of the combination of
international guidelines recommendations and study committee
consensus derived from ED clinical practice:
1st hour:
-age 1 to 2 years: 50 cc of low osmolarity ORS (sodium 60 mmol/L)
administered cold and in small, frequent volumes (small sips, time
divided); this amount correspond to 1/2 coffee spoon (equivalent
to 1,5 cc) every 2 minutes;
-age 3 to 6 years: 100 cc of low osmolarity ORS (sodium 60 mmol/
L) administered cold and in small, frequent volumes (small sips,
time divided); this amount correspond to 1 coffee spoon
(equivalent to 3-3,5 cc) every 2 minutes.
From 2nd to 6th hour:
Cold ORS administered at sips following the plan:
- Mild dehydration: 30-60 ml/Kg body weight over 4-6 hours
- Moderate dehydration: 60-90 ml/Kg body weight over 4-6 hours
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by doctors on call or bedside nurse during the patient
stay in the ED (or any other paediatric unit devoted to
short observation) using a standardized assessment tool.
Patient will be reassessed at 30 minute intervals for a
minimum of 6 hours. During the patients’ hospital stay,
doctors and nurses will be blind to treatment assign-
ment. A telephone follow up call will be made 48 hours
after ED discharge using a standard form by a research
assistant blind to treatment assignment.
Note: We discussed whether to consider hospital
admission as the primary study outcome. Unfortunately,
criteria for hospital admission could differ in different
hospitals and ED settings and various administrative
typologies of hospital admission exist in the study centres,
including the “short observation” which may vary across
centres in the way it is defined and applied. A recent sys-
tematic review on ondansetron confirms that when con-
sidering hospitalization as an outcome, there is great
heterogeneity. Authors indicate different criteria for hos-
pital admission as a possible explanation [15]. Definition
and standardization of hospital admission criteria are
difficult due to differences in the administrative and
organizational characteristics among participating EDs.
Furthermore, nasogastric or intravenous rehydration
represent a more objective outcome and represent any-
way a good proxy measure of hospital admission.
Randomization
Patients will be randomly assigned in fixed block size of
nine to receive ondansetron or domperidone or placebo.
Randomisation list will be generated using STATA soft-
ware and will be stratified according to participating cen-
tres. Randomization procedure will be centralized and
managed by an independent statistician at the Coordinat-
ing Centre. The randomization sequence will be provided
to the central pharmacy, which will prepare and dispense
to participating hospitals active drugs and placebo. After
checking eligibility and failure of first ORS administra-
tion, the next available bag containing drug preparations
will be opened by the doctor on call or by the bedside
nurse and a weigh-appropriate dose will be administered
to patients. All study investigators, personnel, and partici-
pants will be unaware of the randomization procedure
and pharmaceutical preparations assignments.
Blinding
The pharmaceutical preparation will be directly sent to
participating centres in closed, opaque and consecutive
numbered bags by the central pharmacy. Drug prepara-
tions will be indistinguishable by taste, odour and
appearance. All study investigators, personnel, and parti-
cipants will be blind to preparations administered.
Information retrieval
A questionnaire detailing demographic data, medical his-
tory, allergies, history of present illness, and medication
received will be collected at enrolment by doctors on call.
Data relative to study outcomes will be collected by doc-
tors on call or bedside nurse during the hospital stay.
Patient will be reassessed at 30 minute intervals for a
minimum of 6 hours and data will be collected at each
assessment. Forty-eight hours after discharge, a blind
researcher assistant will telephone the child’s family to
evaluate, using a standard form, the gastroenteritis evolu-
tion, the possible need of hospitalisation or readmission
in ED and the final outcome. Paper records will be trans-
ferred by each centre into electronic data base. The per-
centage of subjects lost to follow up, based on available
literature and taking into account the short follow up
period, can be estimated as less than 10% [20,22].
Sample size estimates
Studies comparing ondansetron versus placebo are avail-
able in the literature while it was impossible to identify
studies comparing ondansetron and domperidone. Two
studies evaluating domperidone versus placebo were also
identified, even if characterized by low methodological
quality and small sample size. Based on the available litera-
ture, it appears plausible to hypothesize that ondansetron
is more efficacious in comparison to placebo or domperi-
done and therefore design the study as a superiority trial.
For sample size estimation we specifically referred to the
Roslund RCT [22] that implemented a similar protocol to
ours (enrolment of subjects with clinical acute gastroenter-
itis who failed initial ORS administration in the ED). Tak-
ing into account the above stringent eligibility criteria, we
estimate that the enrolment of 540 children (i.e. 180
patients in each arm) will provide the study with a statisti-
cal power of 80% to detect a change from 50% in placebo
group to 35% in domperidone group and 20% in ondanse-
tron group in the proportion of children requiring naso-
gastric or intravenous rehydration, given a two-sided type
I error of 0,05. Given the lack of available efficacy esti-
mates, domperidone efficacy was estimated as intermedi-
ate between ondansetron and placebo.
Statistical analysis
Baseline characteristics of the three groups will be com-
pared by the chi-square test for proportions and the
analysis of variance or Kruskal-Wallis test (depending
on data distribution) for continuous variables. Relative
risks and 95% confidence intervals will be presented for
categorical data while means and standard deviations for
continuous data. For categorical outcomes, differences
between groups will be evaluated using the chi-square
test; for continuous outcomes using analysis of variance
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Analyses will be performed with STATA software (ver-
sion 9) according to the intention-to-treat principle. All
p values will be two-sided, with a p value of less than
0.05 used to indicate statistical significance.
Safety profile
An adverse event (AE) is any untoward medical occur-
rence in a patient or clinical investigation subject adminis-
tered a pharmaceutical product and which does not
necessarily have a causal relationship with this treatment.
Eligible subjects 
(children attending ED)
Inclusion/exclusion criteria 
Excluded if don't meet 
eligibility criteria
First oral rehydration solution (ORS) 
administration
In case of vomiting or liquid 
refusal
Excluded if ORS success
administration
Enrolled subjects
Excluded if parental consent 
not given
Written parents consent 
j
Oral Ondansetron
0,15 mg/Kg of body weight  
Centralised random allocation to 1 dose of
Oral Domperidone
0,5 mg/Kg of body weight
Oral placebo
Second dose given in case of vomiting within 15 minutes
After 45-60 minutes Æ second ORT 
Outcomes evaluation Outcomes evaluation Outcomes evaluation
Intention to treat analysis
Outcomes evaluation Outcomes evaluation Outcomes evaluation
Patients assessed at 30 minute intervals for a minimum of 4 hours of ED stay. 
Telephone follow up at  48 hours after ED discharge 
Figure 1 Study flow chart.
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sign (including an abnormal laboratory finding, for exam-
ple), symptom, or disease temporally associated with the
use of a medicinal product, whether or not considered
related to the medicinal product. All noxious and unin-
tended responses to a medicinal product related to any
dose should be considered adverse drug reactions (ADRs).
The phrase “responses to a medicinal product” means that
a causal relationship between a medicinal product and an
AE is at least a reasonable possibility i.e. the relationship
cannot be ruled out.
A serious AE (experience) (SAE) or reaction (SAR) is
any untoward medical occurrence that at any dose:
- Results in death
- Is life-threatening event in which the patient was at
risk of death at the time of the event; it does not
refer to an event which hypothetically might have
caused death if it were more severe
- Requires in-patient hospitalization or prolongation
of existing hospitalization
- Results in persistent or significant disability/
incapacity
- Is an important medical event
Medical and scientific judgment should be exercised
in deciding whether expedited reporting is appropriate
in cases of important medical events that may not be
immediately life threatening or result in death or hospi-
talization but may jeopardize the patient or may require
intervention to prevent one of the other outcomes listed
in the definition above. These should also usually be
considered serious.
In the event of the occurrence of any clinical AE or
abnormal laboratory test value that is serious or medically
important during the course of the study or the post-treat-
ment period, irrespective of the treatment received by the
patient, the investigator is obliged to immediately inform
the Coordinating Units. Following a report by phone, writ-
ten information has to be sent by fax or e-mail. Coordinat-
ing Units is solely responsible for sending the reports on
Suspected Unexpected Serious Adverse Reactions (SUS-
ARs) to all participating investigators, to AIFA and Ethics
Committees concerned in accordance with international
and Italian laws and regulations as well as ICH/GCP
guidelines. SUSARs represent Serious Adverse Events
related to study drugs, considered “unexpected” with
regard to the Summary of Product Characteristics.
Discussion
Organizational Characteristics
The study will be coordinated by the Department of
Paediatrics, Institute for Maternal and Child Health -
IRCCS Burlo Garofolo, Trieste and by, Maternal and
Child Health Laboratory, Institute Mario Negri, Milan.
The Coordinating Units will be responsible for the trial
coordination (including training, randomization, study
monitoring, data collection, data analysis, reporting).
Subject will be enrolled in 15 Italian Paediatric Emer-
gency Department Units.
A multidisciplinary (clinicians and epidemiologists)
steering committee will establish to monitor the data, to
ensure patient safety and to act as reference for Partici-
pants Units. Any problem arising during the trial will be
discussed by committee members and decision will be
shared with Participants Unit.
A period of 24 months will be required to carry out
the study. The recruitment period will last 18 months.
Each patient will be recruited at the ED of the partici-
pating centres and followed up every 30 minutes at least
for 6 hours. Each patient will be contacted by phone
48 hours after ED discharge to evaluate long-term out-
comes. Every 8 months research meetings between
Coordinating and Participating Units will be arranged to
discuss research development and address any emerging
issue. The final report will be prepared within the
24 month period.
Good clinical practices and quality control
Various processes will be undertaken in order to guar-
antee the overall quality of the study, and thus to maxi-
mise its validity and reliability:
1. The steering committee will monitor the safety
and the overall quality and scientific integrity of the
study. Any problems arising during the trial, includ-
ing adverse events evaluation, will be discussed by
the committee members and decision will be shared
with Participants Unit. During the study a monitor-
ing visit will be carried out in each centre by mem-
bers of the steering committee;
2. Before the study starts and every 8 months,
research meetings between Coordinating and Partici-
pating Units will be arranged to standardize the pro-
cedures, discuss research developments and address
any emerging issues;
3. Local meeting with nurses and doctors involved in
the field work will be arranged by local study coordi-
nators to train, explain and discuss study procedures
and flow charts;
4. Randomization procedure will be centralized and
managed by an independent statistician at the Coor-
dinating Centre.
5. The pharmaceutical preparation will be prepared
and directly sent to participating centres by a central
independent pharmacy.
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Page 7 of 96. All the documents produced for the study (Clini-
cal research form, electronic database, informed con-
sent) will be standardized;
7. Written documents on the trial process and a
fieldwork manual will be prepared for doctors and
nurses involved in the field work, including instruc-
tions on how to fill in the Clinical research form
and the electronic database;
8. The electronic database will be periodically
checked for accuracy by the Coordinating Units;
9. A progress report will be produced every eight
months by the Coordinating Units.
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Reactions; WHO: World Health Organization
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